UK Markets closed

GlaxoSmithKline plc (GLAXF)


Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
21.25-0.24 (-1.12%)
As of 10:04AM EDT. Market open.
People also watch
NVSEFRHHVFHBCYFBPAQFNSRGF
Full screen
Previous close21.49
Open21.08
Bid0.00 x
Ask0.00 x
Day's range21.08 - 21.25
52-week range18.16 - 22.98
Volume703
Avg. volume1,711
Market cap103.47B
Beta1.17
PE ratio (TTM)47.86
EPS (TTM)0.44
Earnings dateN/A
Dividend & yield0.95 (5.02%)
Ex-dividend date2016-11-03
1y target estN/A
Trade prices are not sourced from all markets
  • Gilead's HIV Drug Matches Glaxo Rival In Late-Stage Trials
    Investor's Business Daily2 hours ago

    Gilead's HIV Drug Matches Glaxo Rival In Late-Stage Trials

    Glaxo shares dipped near a two-week low after Gilead's HIV drug combination proved to be non-inferior in a late-stage trial.

  • Zacks5 hours ago

    The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX

    The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX

  • Reuters11 hours ago

    HIV fight advances with new drug cocktails, fresh vaccine hopes

    Three decades after approval of the first-ever AIDS treatment, HIV medicine is seeing a new wave of innovation with scientists reporting positive data on Monday for improved drug cocktails and a novel experimental vaccine. The Achilles heel for us is drug resistance because the virus is incredibly quick to mutate," Linda-Gail Bekker, deputy director of the Desmond Tutu HIV Centre in South Africa, said. The race for better and more convenient medicines has made HIV a rich battleground for drug companies such as Gilead Sciences and GlaxoSmithKline, which generate billions of dollars from modern therapies.